Incretin receptor agonists, including GLP-1 and dual GIP/GLP-1 agents, have revolutionized the treatment landscape for type 2 diabetes and obesity by positively impacting all components of metabolic syndrome—improving glycemic control, promoting weight loss, and reducing cardiovascular and renal events. However, their high cost and the need for long-term administration remain major barriers to widespread adoption, especially in economically disadvantaged communities. This Research Topic aims to explore how these therapies can be implemented more sustainably and equitably, in alignment with Sustainable Development Goal 3 (Good Health and Well-being) of the United Nations 2030 Agenda, which seeks to ensure healthy lives and promote well-being for all ages.
We invite contributions addressing the following core areas:
•Economic Evaluation: Targeted cost-utility and cost-effectiveness analyses to determine the economic impacts of incretin therapies compared to long-term health benefits, such as diabetes progression, weight loss, and decreased cardiovascular and renal event incidence.
•Health Outcomes Assessment: Assess patient-reported outcomes and health-related quality of life through longitudinal studies and real-world data, employing predictive modeling to evaluate long-term benefits.
•Policy and Drug Utilization: Analyze existing prescription and reimbursement policies, and assess socio-economic and cultural determinants of access, adherence, and equity in the use of incretin-based therapies. This may include: -Drug Utilisation: Describe and evaluate prescribing patterns and patient adherence to incretin-based treatments, considering diverse patient, provider, and contextual factors. -Policy Evaluation: Assess current policies related to the prescribing and reimbursement of incretin-based treatments, with a focus on availability, accessibility, and existing inequalities.
By integrating pharmacoeconomics, patient-centered outcomes, and health policy analysis, this Research Topic provides a multidimensional perspective to generate evidence-based insights aimed at promoting equitable access strategies. The ultimate goal is to support healthcare providers, policymakers, and patients in making informed decisions about resource allocation, treatment strategies, and public health planning.
Article types and fees
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Clinical Trial
Curriculum, Instruction, and Pedagogy
Data Report
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Hypothesis and Theory
Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.
Article types
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Clinical Trial
Curriculum, Instruction, and Pedagogy
Data Report
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Hypothesis and Theory
Methods
Mini Review
Opinion
Original Research
Perspective
Policy and Practice Reviews
Policy Brief
Review
Systematic Review
Technology and Code
Keywords: Incretin receptor agonists, access to diabetes treatment, cost-effectiveness, health equity, prescribing patterns, global health outcomes, Incretin-based therapies, GLP-1 receptor agonists, GIP/GLP-1 dual agonists, semaglutide, tirzepatide, metabolic syndrome, type 2 diabetes, obesity management, pharmacoeconomics, health economics, cost-effectiveness analysis, cost-utility analysis, economic sustainability, healthcare resource allocation, health impact, cardiovascular outcomes, renal outcomes, weight loss, patient-reported outcomes, PROs, health-related quality of life, HRQoL, global health, access to medicines, healthcare policy, drug reimbursement, prescription policy, drug utilization, treatment adherence, health disparities, real-world evidence, real-world data, longitudinal studies, public health planning, Sustainable Development Goal 3, SDG 3, health technology assessment, HTA, chronic disease management, equitable access, pharmaceutical policy, treatment affordability, Mounjaro, Wegovy, Ozempic, Rybelsus, Zepbound, Trulicity, Victoza, Saxenda
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
